<DOC>
	<DOCNO>NCT01677767</DOCNO>
	<brief_summary>This observational study evaluate use clinical practice efficacy Mircera ( methoxy polyethylene glycol-epoetin beta ) chronic kidney disease patient dialysis receive Mircera treatment chronic renal anemia . Eligible patient follow 24 week .</brief_summary>
	<brief_title>An Observational Study Mircera ( Methoxy Polyethylene Glycol-Epoetin Beta ) Chronic Kidney Disease Patients Dialysis With Renal Anemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<criteria>Adult patient , 18 65 year age , inclusive Patients chronic kidney disease dialysis ESA na√Øve Hb &lt; 10 g/dL , treatment ESAs Mircera Hb within target range 1012 g/dL Adequate iron status judge treat physician Hypersensitivity recombinant human erythropoietin , polyethylene glycol constituent study medication Clinically significant concomitant disease disorder define protocol Clinical suspicion pure red cell aplasia ( PRCA ) Planned elective surgery study period , except cataract surgery vascular access surgery Transfusion red blood cell previous 2 month Pregnant woman Contraindications Mircera accord local prescribing information judge investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>